Related Experiment Videos
A controlled trial of methylene blue in severe depressive illness
Biological Psychiatry
|May 1, 1987
Abstract:
Methylene blue, 15 mg/day, was compared with placebo in treatment of severe depressive illness. The 3-week trial was designed to avoid bias by placebo response and also to avoid observer bias. Improvement in patients receiving methylene blue was significantly greater than in those receiving placebo. Methylene blue at a dose of 15 mg/day appears to be a potent antidepressant, and further clinical evaluation is essential.
Insights
Methylene blue, a potential antidepressant, showed significant improvement in severe depressive illness compared to placebo over a 3-week trial. Further clinical evaluation is recommended for this potent treatment.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Severe depressive illness presents a significant challenge in mental healthcare.
- Existing antidepressant treatments have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy of methylene blue as a treatment for severe depressive illness.
- To compare the antidepressant effects of methylene blue against a placebo control.
Main Methods:
- A 3-week clinical trial was conducted involving patients with severe depressive illness.
- Methylene blue (15 mg/day) was administered to one group, while a placebo was given to a control group.
- Study design incorporated measures to mitigate placebo response and observer bias.
Main Results:
- Patients treated with methylene blue demonstrated significantly greater improvement in depressive symptoms compared to the placebo group.
- The observed antidepressant effect was statistically significant.
Conclusions:
- Methylene blue, at a dosage of 15 mg/day, shows promise as a potent antidepressant agent.
- Further extensive clinical evaluation is essential to confirm these findings and establish its therapeutic role.